4D Molecular Therapeutics

Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental…
Read More...

Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial…
Read More...

<!-- Name:DistributionId Value:8741968 --> <!--…
Read More...

EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a…
Read More...

EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a…
Read More...

- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102…
Read More...

4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse…
Read More...

4D-150 designed as an intravitreal gene therapy with dual transgenes expressing aflibercept and VEGF-C RNAi for the…
Read More...